Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Year: 2024
Type: conference-abstract
Source: Blood
Institutions: Takeda (United States), City Of Hope National Medical Center, Hospital Universitari i Politècnic La Fe, University of Alabama at Birmingham, Istituto di Ematologia di Bologna, Oregon Health & Science University, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Josep Carreras Leukaemia Research Institute, Hackensack University Medical Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, First Hospital of Jilin University
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405041173